Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients
FYB206-C1-01
Phase 1 other active
Quick answer
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients for Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection is a Phase 1 program (other) at Formycon AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Formycon AG
- Indication
- Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection
- Phase
- Phase 1
- Modality
- other
- Status
- active